Prof. Wei Tao is the Farokhzad Family Distinguished Chair for Innovation (Endowed Chair) and Principal Investigator at Brigham and Women’s Hospital, Harvard Medical School. He is also the first Distinguished Chair professor as an assistant professor in his institution. His research focuses on biomaterials, nanotechnology and drug delivery, as well as their various applications in translational medicine. He has published over 180 high-impact papers in prestigious journals such as Nature Medicine, Nature Nanotechnology, etc.
Prof. Tao is a Clarivate’s Global Highly Cited Researcher, World's Top 2% Scientist (Career-List, Mendeley Data from Elsevier), and an elected fellow of IAAM. MIT Technology Review previously listed him as one of the top innovators. Microsoft Academic also listed him as one of the Global Top 5 Trending Authors in Nanotechnology, and Top Authors in Nanomedicine. He serves on the scientific committee as an invited reviewer for the European Research Council, NIH (US), Deutsche Forschungsgemeinschaft (German), Swiss National Science Foundation (Switzerland), Dutch Research Council (Netherlands), Israel Science Foundation (Israel), Canadian Institutes of Health Research (Canada), etc. He also serves on numerous editorial boards including as Founding Editor-in-Chief of Biomedical Technology, Deputy Editor of Exploration, Associate Editor of Journal of Nanobiotechnology, and Aggregate; Editor of PNAS; Guest Editor of eLife, etc.; Senior Editorial Board Member of Materials Today, etc.; and Advisory Board Member of Matter (Cell Press).